9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, under its collaboration with fellow UK-based artificial intelligence (AI) company BenevolentAI. 28 January 2021
In what is seen as a unique collaboration, Eli Lilly, Vir Biotechnology and GlaxoSmithKline yesterday announced they were joining forces to evaluate a combination of two COVID-19 therapies in low-risk patients with mild-to-moderate COVID-19. 28 January 2021
A post-marketing safety study of Pfizer’s Xeljanz (tofacitinib) has missed both primary endpoints, threatening to undermine the drug’s competitiveness among rival options. 28 January 2021
The National Institute for Health and Care Excellence (NICE) has recommended the use of Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma in adults. 27 January 2021
Whether politicians choose to accept it or not, the countries of the world are engaged in a race to vaccinate their populations against the novel coronavirus - and winners are already beginning to emerge. 27 January 2021
French pharma major Sanofi today revealed it has entered into an agreement with Germany’s BioNTech under which Sanofi will support manufacturing and supply of BioNTech’s COVID-19 vaccine. 27 January 2021
US President Joe Biden has announced plans to boost vaccine supplies to US states by around 1.4 million doses per week, as the country scrambles to protect itself from the novel coronavirus. 27 January 2021
The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) today issued interim recommendations for the use of the mRNA-1237 vaccine against COVID-19 developed by US biotech Moderna. 26 January 2021
Regeneron Pharmaceuticals today announced positive initial results from an ongoing Phase III clinical trial evaluating REGEN-COV (casirivimab and imdevimab antibody cocktail) used as a passive vaccine for the prevention of COVID-19 in people at high risk of infection (due to household exposure to a COVID-19 patient). 26 January 2021
An inhaled interferon beta-1a treatment from Southampton, UK-based respiratory specialist Synairgen is to be included in a large trial testing agents against the novel coronavirus. 26 January 2021
Pharma Foods International (PFI) has entered into exclusive licensing agreement with fellow Japan-based Mitsubishi Tanabe Pharma (MTPC) for a new therapeutic antibody to treat autoimmune diseases. 26 January 2021
A subsidiary of French nanotechnology expert Nanobiotix, Curadigm, has been selected for the Sanofi iTech awards program, as a “highly promising option” to improve gene therapies. 26 January 2021
US biotech Moderna saw its shares gain 7.5% to $140.84 by late-morning trading today, as it announced encouraging results from in vitro neutralization studies of sera from individuals vaccinated with its Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. 25 January 2021
Roche today announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating the Swiss pharma giant’s investigational bispecific antibody, faricimab, in people living with neovascular or “wet” age-related macular degeneration (nAMD). 25 January 2021
In a significant setback, US pharma giant Merck & Co today announced that it is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591. 25 January 2021
Astellas has announced that construction of new manufacturing lines for aseptic drug products utilizing new modalities and technologies has commenced at Yaizu Technology Center of Astellas Pharma Tech, a production subsidiary of Astellas. 25 January 2021
Germany’s Merck KGaA and New York-based Pfizer have secured a new European approval for the checkpoint blocker Bavencio (avelumab), in bladder cancer. 25 January 2021